Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | SCN4A | P35499 | 5/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.40 |
| ▸ | THPO | P40225 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | MAOA | P21397 | 2/20 | 0.38 |
| ▸ | SCN1A | P35498 | 2/20 | 0.38 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.38 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.38 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.38 |
| ▸ | GBA1 | P04062 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12936636 | 0.80 | TAAR1 (0.43) | TAAR1MAOBTSHRADRA2AADRA2B | |
| SCHEMBL24735105 | 0.79 | TAAR1 (0.40) | TAAR1SCN4ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL28382748 | 0.78 | TAAR1 (0.42) | TAAR1SCN4ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL10851642 | 0.77 | MAOB (0.44) | TAAR1CYP1A2MAOBLMNATSHR | |
| SCHEMBL854787 | 0.74 | TAAR1 (0.38) | TAAR1MAOBADRA2AADRA2BADRA2C | |
| SCHEMBL20324293 | 0.74 | SCN4A (0.50) | TAAR1SCN4ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL4846046 | 0.74 | MAOB (0.45) | TAAR1MAOBLMNATSHRADRA2A | |
| Hydrochloric Acid SCHEMBL21518168 | 0.73 | LMNA (0.51) | TAAR1SCN4ACYP1A2CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL21518135 | 0.73 | LMNA (0.51) | TAAR1SCN4ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL13884107 | 0.73 | MAOB (0.37) | TAAR1MAOBADRA2AADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109863160-B | Nucleoside phosphate compound and preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2022-06-07 | — | — | CN | disclosed |
| US-10899786-B2 | Nucleoside phosphate compound and preparation method and use thereof | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2021-01-26 | — | — | US | disclosed |
| US-20200308214-A1 | NUCLEOSIDE PHOSPHATE COMPOUND AND PREPARATION METHOD AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2020-10-01 | — | — | US | disclosed |
| EP-3560943-A1 | NUCLEOSIDE PHOSPHATE COMPOUND AND PREPARATION METHOD AND USE THEREOF | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2019-10-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200308214-A1 | NUCLEOSIDE PHOSPHATE COMPOUND AND PREPARATION METHOD AND USE THEREOF | PNP, NTPCR, TYMP | TAAR1 4584/4885SCN4A 1831/4885CYP1A2 1293/4885 |
| US-10899786-B2 | Nucleoside phosphate compound and preparation method and use thereof | PNP, NTPCR, TYMP | TAAR1 4584/4885SCN4A 1831/4885CYP1A2 1293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.